187 related articles for article (PubMed ID: 29571871)
1. Nivolumab-induced myositis: A case report and a literature review.
Bourgeois-Vionnet J; Joubert B; Bernard E; Sia MA; Pante V; Fabien N; Honnorat J; Streichenberger N
J Neurol Sci; 2018 Apr; 387():51-53. PubMed ID: 29571871
[No Abstract] [Full Text] [Related]
2. Nivolumab-associated immune-related filamentary keratitis.
Madeira M; Fernandes C; Filipe H
BMJ Case Rep; 2024 Apr; 17(4):. PubMed ID: 38688575
[TBL] [Abstract][Full Text] [Related]
3. Atezolizumab-induced myositis in a patient with small-cell lung cancer.
Sahin E; Cabuk D; Tuncer Kuru F; Yazici A
J Oncol Pharm Pract; 2024 Jan; 30(1):220-224. PubMed ID: 37750202
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab-induced SJS/TEN-like reaction.
Fazelpour S; Gibson F; Caligayahan M; Vashi N
Arch Dermatol Res; 2024 May; 316(6):264. PubMed ID: 38795166
[No Abstract] [Full Text] [Related]
5. Nivolumab-induced acute neutrophilic gastritis: Case report in a tertiary hospital.
Ojeda Gómez A; Pamies Ramón MI; Brotons Brotons A; Jiménez García N; Picó Sala MD; Cabezas Macian M; Vera Sánchez JS; García Sepulcre MF
Gastroenterol Hepatol; 2024 Jan; 47(1):74-75. PubMed ID: 36716927
[No Abstract] [Full Text] [Related]
6. Umbilical lichen planus induced by nivolumab.
Martos-Cabrera L; Lladó I; Fernández-Rico P; Butrón-Bris B; Rodríguez-Jiménez P
An Bras Dermatol; 2023; 98(5):712-714. PubMed ID: 37164791
[No Abstract] [Full Text] [Related]
7. Pruriginous vesicular eruption associated with nivolumab immunotherapy: A case of dermatitis herpetiformis.
Housset M; Fayad Kazour A; Paugam C; Le Corre Y; Croue A; Martin L; Lechevalier D; Berthin C
Ann Dermatol Venereol; 2024 Jun; 151(2):103269. PubMed ID: 38678772
[No Abstract] [Full Text] [Related]
8. Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy.
Finazzi T; Rordorf T; Ikenberg K; Huber GF; Guckenberger M; Garcia Schueler HI
BMC Cancer; 2018 Apr; 18(1):395. PubMed ID: 29625593
[TBL] [Abstract][Full Text] [Related]
9. Association of Inflammatory Markers with Disease Progression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors.
Pan M; Alavi M; Herrinton LJ
Perm J; 2018; 22():17-149. PubMed ID: 29616914
[TBL] [Abstract][Full Text] [Related]
10. Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study.
Kobayashi T; Iwama S; Yasuda Y; Okada N; Tsunekawa T; Onoue T; Takagi H; Hagiwara D; Ito Y; Morishita Y; Goto M; Suga H; Banno R; Yokota K; Hase T; Morise M; Hashimoto N; Ando M; Kiyoi H; Gotoh M; Ando Y; Akiyama M; Hasegawa Y; Arima H
J Endocr Soc; 2018 Mar; 2(3):241-251. PubMed ID: 29600292
[TBL] [Abstract][Full Text] [Related]
11. Resolution of Infliximab-Refractory Nivolumab-Induced Acute Severe Enterocolitis After Cyclosporine Treatment in a Patient with Non-Small Cell Lung Cancer.
Iyoda T; Kurita N; Takada A; Watanabe H; Ando M
Am J Case Rep; 2018 Mar; 19():360-364. PubMed ID: 29581417
[TBL] [Abstract][Full Text] [Related]
12. Type 1 diabetes in a melanoma patient treated with ipilimumab after nivolumab.
Omodaka T; Kiniwa Y; Sato Y; Suwa M; Sato M; Yamaguchi T; Sato A; Miyake T; Okuyama R
J Dermatol; 2018 Oct; 45(10):e289-e290. PubMed ID: 29667767
[No Abstract] [Full Text] [Related]
13. Clinical assessment of immune-related adverse events.
Sosa A; Lopez Cadena E; Simon Olive C; Karachaliou N; Rosell R
Ther Adv Med Oncol; 2018; 10():1758835918764628. PubMed ID: 29623110
[TBL] [Abstract][Full Text] [Related]
14. PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients: Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer.
Resch I; Shariat SF; Gust KM
Memo; 2018; 11(1):43-46. PubMed ID: 29606979
[TBL] [Abstract][Full Text] [Related]
15. Responses in patients receiving sequential paclitaxel post progression on PD1 inhibitors.
Sukari A; Nagasaka M; Abdallah N
Oral Oncol; 2018 May; 80():100-102. PubMed ID: 29605290
[TBL] [Abstract][Full Text] [Related]
16. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA
Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint inhibitors and acute myelogenous leukemia: promises and challenges.
Alfayez M; Borthakur G
Expert Rev Hematol; 2018 May; 11(5):373-389. PubMed ID: 29589969
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and toxicity of ipilimumab used after nivolumab in patients with melanoma.
Sato M; Uhara H; Koga H; Okuyama R
J Dermatol; 2018 Oct; 45(10):e287-e289. PubMed ID: 29655228
[No Abstract] [Full Text] [Related]
19. Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity.
Martinez-Calle N; Rodriguez-Otero P; Villar S; Mejías L; Melero I; Prosper F; Marinello P; Paiva B; Idoate M; San-Miguel J
Haematologica; 2018 Jul; 103(7):e318-e321. PubMed ID: 29650641
[No Abstract] [Full Text] [Related]
20. Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer.
Ostios-Garcia L; Faig J; Leonardi GC; Adeni AE; Subegdjo SJ; Lydon CA; Rangachari D; Huberman MS; Sehgal K; Shea M; VanderLaan PA; Cheng MP; Marty FM; Hammond SP; Costa DB; Awad MM
J Thorac Oncol; 2018 Jul; 13(7):1037-1042. PubMed ID: 29631035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
